Premium
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC‐IE): a novel, intensive induction chemotherapy regimen for patients with high‐risk multiple myeloma
Author(s) -
BALLESTER O. F.,
MOSCINSKI L. C.,
FIELDS K. K.,
HIEMENZ J. W.,
ZORSKY P. E.,
GOLDSTEIN S. C.,
SABA H. I.,
SPIERS A. S. D.,
KRONISH L.,
SULLIVAN P.,
ELFENBEIN G. J.
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.d01-2083.x
Subject(s) - idarubicin , medicine , etoposide , cyclophosphamide , multiple myeloma , anthracycline , regimen , dexamethasone , neutropenia , gastroenterology , chemotherapy , surgery , oncology , cytarabine , cancer , breast cancer
We evaluated toxicities and responses to a novel, dose intensive and time sequenced, chemotherapy programme (DC‐IE) in 45 patients with high‐risk myeloma. DC‐IE consisted of: dexamethasone (days 1–4); cyclophosphamide (day 5); idarubicin and etoposide (days 8–10). Complete response (CR) was achieved in four patients, six patients achieved near complete responses (nCR) and 21 patients achieved a partial remission (PR). Overall response rate was 76% (CI 56–94%) for newly diagnosed patients ( n =21) and 62% (CI 36–81%) for relapsed/refractory patients ( n =24). Toxicities were limited to myelosupression; two patients died of sepsis during neutropenia (4%). DC‐IE is active and tolerable for high‐risk multiple myeloma, including patients with relapsed or refractory disease to anthracycline containing regimens.